Modification of Serum Brain-Derived Neurotrophic Factor Levels Following Anti-HCV Therapy with Direct Antiviral Agents: A New Marker of Neurocognitive Disorders

摘要

Background: A large number of central nervous system impairments occur in subjects with chronic HCV infection regardless ofliver disease. Brain-derived neurotrophic factor (BDNF) plays an essential role in the adult brain concerning its development andproper functioning. Our study aimed at contributing to the discussion on the involvement of BDNF in neurocognitive disordersassociated with HCV infection.Objectives: We aimed to evaluate the prevalence of neurocognitive disorders in a cohort of HCV-infected subjects, tomeasure serumBDNF levels in the same cohort according to the degree of neurocognitive disorders, and to evaluate serum BDNF level modificationin HCV-infected patients after direct antiviral agents (DAA) therapy.Methods: We enrolled patients scheduled for DAA therapy in January 2018 from three infectious disease units in Eastern Sicily. Eachparticipant was evaluated for neurocognitive status with MoCA score at baseline and 12 and 24 weeks after the end of therapy. Moreover,we measured serum BDNF levels at baseline and 12 weeks after the end of therapy.Results: Of 70 HCV-infected patients, 42 (60%) were males. The average age was 57 ± 19 years and the average ALT level was 79 ±24 UI/mL; 38 (54.3%) individuals had HCV genotype 1 infection and 23 (32.8%) and 25 (35.7%) individuals had F1 and F2 fibrosis stages,respectively. Moreover, 67 (95.7%) individuals achieved sustained virological response. The MoCA score at baseline identified fourgroups of patients. Higher MoCA scores 24 weeks after the end of therapy highlighted the improvement of neurocognitive statusin all groups. Serum BDNF levels in the same four groups, measured 12 weeks after the end of DAA therapy, appeared significantlymodified compared to baseline serum BDNF levels, matching the improvement of MoCA score results obtained 24 weeks after DAAtherapy.Conclusions: The serum BDNF level may represent a useful marker of cognitive dysfunction in patients with HCV infection and auseful index for assessing the post-therapy follow-up.